ImmunogenX Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
6
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$60.1M
ImmunogenX General Information
Description
Operator of a biotherapeutics company intended to cater to celiac disease research. The company engages in developing latiglutenase, a potentially first-in-class, targeted, oral biotherapeutics and a digestive enzyme that degrades unintended ingestion of gluten in the body, enabling doctors to enhance the life of celiac disease patients.
Contact Information
Website
www.immunogenx.comCorporate Office
- 1600 Dove Street
- Suite 330
- Newport Beach, CA 92660
- United States
Corporate Office
- 1600 Dove Street
- Suite 330
- Newport Beach, CA 92660
- United States
ImmunogenX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 13-Mar-2024 | $60.1M | Completed | Clinical Trials - Phase 3 | ||
| 6. Grant | 08-Sep-2020 | Completed | Clinical Trials - General | |||
| 5. Grant | 01-Mar-2020 | Completed | Clinical Trials - General | |||
| 4. Grant | 01-Jan-2019 | Completed | Clinical Trials - General | |||
| 3. Accelerator/Incubator | 28-Oct-2016 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series B) | 23-Oct-2015 | $5M | $5M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 22-Apr-2014 | Completed | Clinical Trials - General |
ImmunogenX Signals
ImmunogenX Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Center For Complementary And Integrative Health | Government | |||
| National Institute for Allergy and Infectious Disease | Government | |||
| National Institute of Diabetes and Digestive and Kidney Diseases | Government | |||
| National Institutes of Health | Government | |||
| Octane (California) | Accelerator/Incubator |
ImmunogenX Investments (1)
ImmunogenX’s most recent deal was a Corporate Asset Purchase with Alvine Pharmaceuticals (Asstes). The deal was made on 15-Mar-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Alvine Pharmaceuticals (Asstes) | 15-Mar-2016 | Corporate Asset Purchase | Buildings and Property |
ImmunogenX FAQs
-
When was ImmunogenX founded?
ImmunogenX was founded in 2013.
-
Where is ImmunogenX headquartered?
ImmunogenX is headquartered in Newport Beach, CA.
-
What is the size of ImmunogenX?
ImmunogenX has 6 total employees.
-
What industry is ImmunogenX in?
ImmunogenX’s primary industry is Drug Discovery.
-
Is ImmunogenX a private or public company?
ImmunogenX is a Private company.
-
What is the current valuation of ImmunogenX?
The current valuation of ImmunogenX is .
-
What is ImmunogenX’s current revenue?
The current revenue for ImmunogenX is .
-
How much funding has ImmunogenX raised over time?
ImmunogenX has raised $5M.
-
Who are ImmunogenX’s investors?
National Center For Complementary And Integrative Health, National Institute for Allergy and Infectious Disease, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and Octane (California) have invested in ImmunogenX.
-
When was ImmunogenX acquired?
ImmunogenX was acquired on 13-Mar-2024.
-
Who acquired ImmunogenX?
ImmunogenX was acquired by Grid AI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process